Author

C. Scholl

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Cell Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 4 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2

Frequent Co-Authors

A. Banito· 2 shared C. Erkut· 2 shared H. Glimm· 2 shared R. Imle· 2 shared S. Froehling· 2 shared W. Hartmann· 2 shared A. Carazzato· 1 shared A. Kuntze· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Banito

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Exploiting WEE1 kinase activity as FUS::DDIT3-dependent therapeutic vulnerability in myxoid liposarcoma

L. Heinst, K. S. Lee, R. Berthold, I. Isfort, S. Wosnig, A. Kuntze, S. Hafner, B. Altvater, C. Roessig, P. Aman, E. Wardelmann, C. Scholl, W. Hartmann, S. Froehling, M. Trautmann

This study identifies WEE1 kinase activity as a therapeutic target in FUS::DDIT3-driven myxoid liposarcoma by showing its role in replication stress tolerance and cell survival.

Clinical Cancer Research · Aug 29, 2024Peer-reviewedCancer Biology

Somatic gene delivery for flexible in vivo modeling of high-risk sarcoma

R. Imle, D. Blosel, F. Kommoss, E. Zhao, R. Autry, C. Blume, D. Lupar, L. Schmitt, C. Winter, L. Wagner, S. Placke, M. von Eicke, M. Hertwig, H. Peterziel, I. Oehme, , A. Banito

This paper develops a mouse model for high-risk sarcoma by delivering genetic lesions via electroporation, generating multiple sarcoma types and validating their molecular and therapeutic relevance.

bioRxiv · Jan 30, 2024 · PreprintCancer Biology

Multidimensional Characterization of Soft-Tissue Sarcomas with FUS-TFCP2 or EWSR1-TFCP2 Fusions

J. Schopf, S. Uhrig, C. E. Heilig, K.-S. Lee, T. Walther, A. Carazzato, A. M. Dobberkau, D. Weichenhan, C. Plass, M. Hartmann, G. D. Diwan, Z. Carrero, C. R. Ball, T. Hohl, T. Kindler, , C. Scholl

This study characterizes soft-tissue sarcomas with FUS-TFCP2 or EWSR1-TFCP2 fusions through multi-omics analyses and functional studies, identifying therapeutic targets and mechanisms of disease.

bioRxiv · Feb 19, 2023Cancer Biology

Cell division tracing combined with single-cell transcriptomics reveals new cell types and differentiation paths in the regenerating mouse lung

L. R. Martins, L. Sieverling, M. Michelhans, C. Schiller, C. Erkut, S. Triana, S. Froehling, L. Velten, H. Glimm, C. Scholl

bioRxiv · Jan 18, 2023Cell Biology

Shallow nanopore RNA sequencing enables transcriptome profiling for precision cancer medicine

A. Mock, M. Braun, C. Scholl, S. Fröhling, C. Erkut

This study evaluates shallow nanopore RNA sequencing for transcriptome profiling in cancer, showing it is rapid, cost-effective, and comparable to Illumina for key analyses.

bioRxiv · May 31, 2022Cancer Biology

Effects of genetic variability of CYP2D6 on neural substrates of sustained attention during on-task activity

R. Viviani, I. Messina, J. E. Bosch, L. Dommes, A. Paul, K. L. Schneider, C. Scholl, J. C. Stingl

This study investigates how CYP2D6 genetic variants affect neural activity during attention tasks, finding that rapid metabolizers show reduced cognitive efficiency compared to poor metabolizers.

bioRxiv · Oct 9, 2020Pharmacology & Toxicology